Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of “Buy” from Analysts

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have earned an average recommendation of “Buy” from the thirteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $107.9091.

A number of equities research analysts recently weighed in on the company. Chardan Capital reaffirmed a “buy” rating and set a $100.00 price target on shares of Monopar Therapeutics in a report on Monday, March 30th. Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. BTIG Research reaffirmed a “buy” rating and set a $104.00 price target on shares of Monopar Therapeutics in a report on Monday, February 23rd. Piper Sandler set a $105.00 price target on Monopar Therapeutics in a report on Tuesday, June 2nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Monopar Therapeutics in a report on Tuesday, June 2nd.

Monopar Therapeutics Price Performance

MNPR stock opened at $59.48 on Monday. The business has a fifty day moving average price of $58.16 and a 200 day moving average price of $63.53. Monopar Therapeutics has a fifty-two week low of $29.18 and a fifty-two week high of $105.00. The stock has a market capitalization of $398.52 million, a price-to-earnings ratio of -31.31 and a beta of 1.52.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. On average, equities analysts expect that Monopar Therapeutics will post -2.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE increased its stake in shares of Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after buying an additional 53,336 shares during the period. ADAR1 Capital Management LLC increased its stake in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of Monopar Therapeutics in the 1st quarter valued at $250,000. Siren L.L.C. increased its stake in shares of Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after buying an additional 57,820 shares during the period. Finally, Sei Investments Co. increased its stake in shares of Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after buying an additional 656 shares during the period. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.